Answers are grounded in this paper and cite their sources.
The MAPK pathway activity in CJM is increased, not only as a consequence of the BRAF V600E mutation. Targeted therapy may be useful for patients with CJM, especially those with activating BRAF mutations, whereas NRAS-mutated melanomas are relatively resistant.
No takes yet. Share an insight, caveat, or question.
Zaoui et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: